Immuneering Corp — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Immuneering hired Andrew Gengos as Chief Financial Officer effective June 10, 2026, with base salary of $530,000/year, target bonus of 40% ($212,000), and non-qualified stock option grant of 650,000 shares vesting over 4 years at fair market value exercise price. Standard severance package includes 1x base salary continuation if terminated without cause and equity acceleration in change-of-control scenario.
Why this rating
C-suite hire is routine for a public biotech company; equity grant (~$17.6M at ~$27/share) is ~17% of $101M market cap but standard for CFO role. No business-altering event.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.